|Articles|April 9, 2014

Karyopharm Therapeutics Inc. and Clinipace Worldwide Announce Preferred Provider Agreement

Clinipace Worldwide announced it has entered into a preferred provider agreement with Karyopharm Therapeutics Inc.

Clinipace Worldwide announced it has entered into a preferred provider agreement with Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The preferred provider agreement is part of a longer-term strategic partnership that would see Clinipace managing several clinical programs, including oncology, wound healing, and other diseases, on behalf of Karyopharm in 2014.

Read the full release here.


Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.